[Worldwide experience with enalapril].
Up to now, the experiments carried out throughout the world with enalapril have been most encouraging. The drug gives good, even excellent responses in 54 to 66 % of patients with essential hypertension, and it is at least as effective as diuretics and beta-blockers. Compared with those of diuretics, the effects of enalapril confirm that the best responders are those patients who are most dependent on the renin-angiotensin system. When a diuretic is administered concomitantly with enalapril, almost all patients respond and the therapeutic effect is well maintained in long term. Blocadren or alpha-methyldopa can be added to hydrochlorothiazide, thus providing additional benefits to patients with severe hypertension. Enalapril reduces the undesirable metabolic effects of hydrochlorothiazide, particularly hypokalaemia. Altogether, enalapril and captopril have similar effectiveness, but enalapril is better tolerated and does not seem to produce the side-effects encountered with captopril, notably skin rashes and ageusia. As expected, enalapril and other angiotensin-converting enzyme inhibitors may be associated with azotaemia in patients with bilateral renovascular hypertension.
D002216:Captopril / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000453:epidemiology; D004656:Enalapril / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006073:Gout / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced; D007958:Leukocyte Count
D004656:Enalapril; D002216:Captopril
L'énalapril dans les expériences mondiales.